Cationic Liposomal Co-delivery of Small Interfering RNA and a MEK Inhibitor for Enhanced Anticancer Efficacy

被引:0
作者
Seung Hee Kang
Hee-Jeong Cho
Gayong Shim
Sangbin Lee
Su-Hyeon Kim
Han-Gon Choi
Chan-Wha Kim
Yu-Kyoung Oh
机构
[1] Korea University,School of Life Sciences and Biotechnology
[2] Seoul National University,College of Pharmacy and Research Institute of Pharmaceutical Sciences
[3] Hanyang University,College of Pharmacy
来源
Pharmaceutical Research | 2011年 / 28卷
关键词
co-delivery; combination therapy; liposome; MEK inhibitor; siRNA;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:3069 / 3078
页数:9
相关论文
共 155 条
[1]  
Kato T(2010)Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells Gene Ther. 17 1363-72
[2]  
Natsume A(2009)Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells Mol Cancer Ther. 8 3162-70
[3]  
Toda H(2008)RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy Cancer Res. 68 7975-84
[4]  
Iwamizu H(2010)The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance Biomaterials. 31 358-65
[5]  
Sugita T(2009)Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells Small. 5 2673-7
[6]  
Hachisu R(2010)Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line ACS Nano. 4 4539-50
[7]  
Simonin K(2010)Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer J Biol Chem. 285 22639-50
[8]  
Brotin E(2010)Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations Mol Cancer Ther. 9 3137-44
[9]  
Dufort S(2007)Clinical experience of MEK inhibitors in cancer therapy Biochim Biophys Acta: Mol Cell Res. 1773 1248-55
[10]  
Dutoit S(2010)A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res. 16 2450-7